Whitney Tilson Says Exact Sciences (EXAS) Still a Great Short
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Exact Sciences to Host Webcast and Conference Call Regarding U.S. Preventive Services Task Force Draft Recommendations
October 6, 2015 7:50 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss the U.S. Preventive Services Task Force release of its draft recommendations regarding colorectal cancer screening.
U.S. Preventive Services Task Force Webcast and Conference Call Details
  Date:  Tuesday, Oct. 6, 2015 Time: 9 a.m. ET, 8 a.m. CT... MoreCologuardĀ® Included as Alternative Screening Test under Draft USPSTF Guidelines
October 5, 2015 8:21 PM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.
USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for colorectal cancer screening starting at age 50 and continuing until age 75.... More

